September 11, 2024 - 🧬 [nGram] Today’s Oncology Scoop: Pfizer at ESMO, Viridian & REVEAL Genomics Results


  1. Viridian Therapeutics announces positive topline results from veligrotug (VRDN-001) phase 3 THRIVE clinical trial in patients with active thyroid eye disease
    • Viridian Therapeutics reported positive topline data from the THRIVE phase 3 trial of veligrotug (VRDN-001) in patients with active thyroid eye disease (TED).
    • The trial met primary and all secondary endpoints at 15 weeks, showing significant improvements in proptosis, clinical activity score, and diplopia.
    • Veligrotug demonstrated a rapid onset of action, with 53% of patients achieving a proptosis response after just one infusion.
    • The safety profile was favorable, with most adverse events being mild and a low rate of discontinuations.
    Read more

  2. Reveal Genomics announces positive top-line results for HER2DX in CLEOPATRA phase III trial
    • Reveal Genomics released positive results for HER2DX, a genomic test for HER2+ breast cancer, from the CLEOPATRA phase III trial.
    • The HER2DX ERBB2 mRNA score showed a strong association with progression-free survival (PFS) and overall survival (OS) in 214 patients.
    • The CLEOPATRA trial compared docetaxel-trastuzumab with and without pertuzumab, leading to FDA approval of pertuzumab in 2012.
    • Detailed results will be presented at an upcoming medical congress and submitted for publication.
    Read more

  3. Incendia Therapeutics enrolls first patient in Phase 1c clinical trial of PRTH-101
    • Incendia Therapeutics has enrolled the first patient in the Phase 1c study of PRTH-101 for advanced or metastatic solid tumors.
    • The study will evaluate the safety, tolerability, and anti-tumor activity of PRTH-101 as a monotherapy and in combination with pembrolizumab.
    • PRTH-101 targets DDR1, a collagen binding protein, to disrupt tumor-associated collagen alignment and permit immune cell access.
    • The trial aims to enroll up to 270 patients in the US and will inform the design of the Phase 2/3 program.
    Read more

  4. Delta-Fly Pharma initiates phase I/II combo-study of DFP-10917 with Venetoclax in AML patients
    • Delta-Fly Pharma has initiated a Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) for AML patients.
    • The trial targets patients who had one prior treatment with a VEN-involved regimen.
    • The first patient was enrolled at the University of Virginia Hospital.
    • The study aims to enroll up to 39 patients, with endpoints including complete remission (CR) rate and progression-free survival (PFS).
    Read more

  5. Pfizer highlights diverse oncology portfolio and combination approaches at ESMO 2024
    • Pfizer will present data from over 50 research abstracts at ESMO 2024, including more than 10 oral and mini-oral presentations.
    • Key presentations include updated results from the Phase 2 PHAROS study of BRAFTOVI + MEKTOVI in BRAF V600E-mutant metastatic NSCLC.
    • Pfizer will share early results for two novel investigational antibody-drug conjugates and a novel combination of next-generation CDK inhibitors.
    • Additional presentations will cover the efficacy and safety of ponsegromab for cancer-associated cachexia and early clinical-stage research for several priority pipeline areas.
    Read more

  6. Avistone announces results from a sponsored clinical research program studying the combination of two small-molecule c-MET and EGFR inhibitors in NSCLC patients at the 2024 World Conference on Lung Cancer (WCLC)
    • Avistone Biotechnology presented results at the IASLC 2024 World Conference on Lung Cancer.
    • The study involved 44 NSCLC patients with EGFR mutation-positive, MET amplified, or MET overexpression.
    • Objective responses were observed in 59.4% of response-evaluable patients, with a 75% ORR in patients with brain metastases.
    • The most common treatment-related adverse events (TRAEs) were rash and paronychia, with no treatment discontinuations due to TRAEs.
    Read more

  7. Scholar Rock completes enrollment in Phase 2 EMBRAZE proof-of-concept trial of apitegromab in obesity
    • Scholar Rock has completed enrollment in the Phase 2 EMBRAZE trial for apitegromab, targeting obesity.
    • The trial aims to evaluate the efficacy, safety, and pharmacokinetics of apitegromab in adults on GLP-1 RA therapy.
    • Primary endpoint: change in lean mass at 24 weeks, with results expected in Q2 2025.
    • Data from this trial will inform the development of SRK-439, a novel myostatin inhibitor for cardiometabolic disorders.
    Read more

  8. Basking Biosciences doses first patients in phase 2 clinical trial of reversible thrombolytic BB-031 for acute ischemic stroke
    • Basking Biosciences has initiated patient enrollment in the RAISE Phase 2 clinical trial for BB-031.
    • The trial will evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of BB-031 in 156 patients.
    • RAISE is a multicenter, double-blind, placebo-controlled, randomized single ascending dose study.
    • BB-031 targets von Willebrand Factor (vWF) and aims to offer a safer, more effective thrombolytic option for acute ischemic stroke patients.
    Read more

  9. Stoke Therapeutics presents zorevunersen data showing substantial reductions in seizures and improvements in cognition and behavior
    • Stoke Therapeutics presented data at the 15th European Epilepsy Congress showing zorevunersen's potential as a disease-modifying treatment for Dravet syndrome.
    • Phase 1/2a ADMIRAL study showed significant reductions in seizures and improvements in cognition and behavior within the first year of treatment.
    • Two-year natural history study indicated high seizure rates and developmental plateau despite standard anti-seizure medications.
    • Plans for a Phase 3 registrational study are underway, focusing on dose regimen and clinical endpoints.
    Read more

  10. Inflammasome Therapeutics completes enrollment in study for first oral dual inflammasome inhibitor for ophthalmic and neuroinflammatory diseases
    • Inflammasome Therapeutics has completed enrollment for a Phase I PK/Safety study of K9, a brain- and retina-penetrant drug.
    • K9 targets multiple neuroinflammatory and degenerative diseases, including Alzheimer's, MS, ALS, Parkinson's, and autoimmune diseases like lupus.
    • The drug blocks two specific inflammasomes, showing superior results compared to single inflammasome inhibitors.
    • The successful completion of this study paves the way for further clinical trials expected to commence later this year.
    Read more